Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
about
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsCYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsDeterminants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapyGetting to 90-90-90 in paediatric HIV: What is needed?Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypesPredictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationNeurological and psychiatric adverse effects of antiretroviral drugs.Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.Neuropsychiatric Effects of HIV Antiviral Medications.Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersPopulation pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.Absence seizures associated with efavirenz initiationPharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphismEfavirenz for HIV-1 infection in adults: an overview.Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionA pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenPharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.Neuropsychiatric side effects of efavirenz therapy.Efavirenz: a review."One pill, once daily": what clinicians need to know about Atriplatrade mark.Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIVADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Clinical pharmacokinetics of antiretroviral drugs in older persons.
P2860
Q21245026-2B441491-110F-49CE-A92F-CB039088EC25Q24606937-FD1E4FB6-326D-4405-88F3-2F603D0441D4Q24609011-75E527D6-F58D-4169-845A-47463F6634C0Q27012807-C38E5C0D-5EA8-41B9-9DA9-11FA90FCA51FQ28293875-464ADB3D-64ED-48C2-AD50-4B279020FAADQ28478666-885FD6E1-F6D1-4581-9848-3BDBD9FDCAEDQ30385352-6E991CC3-69E0-4FAA-B31D-74EE16FDA811Q31150044-2BC25790-0CDB-49FA-ADBE-E995D2A59E88Q33269667-F2B5CF70-85BE-4706-9D91-FC27DF0102E4Q33821729-B1D9B87C-133F-4F0A-A511-78F82B41FA87Q34015667-6E874624-C33F-4657-A276-8D6BDB66D15CQ34039419-7E4B0E18-B184-4B7B-B228-32977CFEF41DQ34282609-C7252AC7-36F0-4F4B-8CDF-EA8358E70BB3Q34464997-EF79B6F7-FA7D-4B0B-89ED-105CD380AD82Q34537705-4C3D34FC-8E87-46CE-84AB-019DC4B08E1DQ34577449-E5D5640F-8CB2-48CB-A87E-241C1225A0A9Q34737523-D6ABE06C-EEE1-471E-A2E8-09B9D55569B6Q35018246-ECA2B898-76F6-4F67-BA5B-75780F243E63Q35065867-DE50ED2D-86EB-4C88-96AD-1B477A49BFE8Q35364120-90604C10-9B10-4F45-AEBD-F140C4273AD3Q35518558-497AC422-2B19-4B6E-8FB9-4DFC25142440Q35547723-32082976-4F7D-4134-8EAF-5D72EAC88380Q35752638-2B564DE6-1D11-4C58-9076-B00AF1946D87Q35827367-A3FEDAC3-7471-40EC-9CA9-D1FBE3097BD6Q35827416-73A7B90A-B054-4142-9E2E-24F5C58B91EFQ35917519-A4CD6C3A-BDF6-4B46-AFC2-AECC541262A1Q35947529-9BFAB217-0909-4AC5-8186-865A640ECE03Q36094233-7A865292-057E-4F32-AF0B-9CAE025FAA19Q36263781-86D3278F-3D59-4162-982C-17DFCC83E3B9Q36349683-401684D4-06F9-4E86-A84D-3D70B81385D7Q36468146-93D8E5CD-DC8D-4706-A61A-07354DE294D2Q36544977-55510E67-5A2D-41A5-B5A7-42F9704E2379Q36558327-1FE4842A-70DE-43B4-A1D8-06091D3E615DQ36762436-15D0F833-16E9-4E13-8504-305F63A1AE2CQ36787311-3E3C02CC-DAF9-474D-BD29-CC752D03D265Q36823570-65854C92-F57D-4021-B679-EAFB4631BDDBQ36840809-EB321385-101E-4774-AD03-56580E3333C8Q36845126-22CBF397-92A3-4493-9DFD-62B7343E5CA2Q36885659-AB250FAB-681B-4695-BD41-4C877409C1F3Q36905884-730452D6-02E4-44EF-9391-A4DED6FACC47
P2860
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Population pharmacokinetics an ...... unodeficiency virus infection.
@en
Population pharmacokinetics an ...... unodeficiency virus infection.
@nl
type
label
Population pharmacokinetics an ...... unodeficiency virus infection.
@en
Population pharmacokinetics an ...... unodeficiency virus infection.
@nl
prefLabel
Population pharmacokinetics an ...... unodeficiency virus infection.
@en
Population pharmacokinetics an ...... unodeficiency virus infection.
@nl
P2093
P50
P356
P1476
Population pharmacokinetics an ...... unodeficiency virus infection.
@en
P2093
Amalio Telenti
Catia Marzolini
Jérôme Biollaz
Karin Fattinger
P356
10.1067/MCP.2003.22
P407
P577
2003-01-01T00:00:00Z